SEARCH published: No CV benefit on reducing homocysteine


June 22, 2010 | Sue Hughes

Oxford, UK – Substantial long-term reductions in blood homocysteine levels with folic-acid and vitamin-B12 supplementation did not have beneficial effects on vascular outcomes in the large-scale SEARCH trial [1]. But a silver lining of good news from the trial is that the vitamin supplements were not associated with any increase in cancer risk, which had been suggested in a previous study.

The trial, published in the June 23, 2010 issue of the Journal of the American Medical Association, was conducted by a team led by Dr Jane M Armitage (University of Oxford, UK).

Results from SEARCH were first reported by heartwire at the 2008 AHA meeting.

Continue reading

Baby-boomers facing time-bomb of cardiovascular diseases

Executive Summary

Australians born before 1955 now represent just over 25% of the population. These Australians may be dubbed ‘Generation Risk’ given the prevalence of risk factors for cardiovascular events (heart attack, stroke or death) in this growing population.
This major study has estimated the five year cardiovascular disease (CVD) risk spectrum of Australians aged 55 years and over. It includes a review of the significant burden CVD imposes each year, the prevalence of eight known CVD risk factors, an estimation of absolute five year CVD risk prevalence in 2010, and the impact population growth and ageing will have on absolute CVD risk prevalence in the next 20 years.
The study classified Australians aged 55 years of over according to their risk of experiencing a fatal or non-fatal CVD event in the next five years, from Mild ‘mid range’ (2.5%≤CVD<5%) to Extreme (CVD≥30%) risk. The findings are compelling. Click here to download the Access Economics ReportContinue reading